Vol. 2 No. 8 (2022)
Reimbursement Recommendations

Zanubrutinib (Brukinsa)

Published August 15, 2022

Key Messages

  • CADTH recommends that Brukinsa (zanubrutinib) should not be reimbursed by public drug plans for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least 1 prior therapy.
  • While evidence from 2 clinical trials showed a response in patients treated with Brukinsa, there is uncertainty in how well patients respond to Brukinsa and how Brukinsa compares to other treatment for MCL.
  • There was no evidence demonstrating improvement in quality of life, since there was no quality of life evidence collected in either clinical trial.
  • It is unclear whether Brukinsa meets the following needs identified by patients: faster remission and longer life, disease and symptom control, better quality of life, and fewer side effects.